Go to deals
Healthcare

LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Service
M&A sell-side
Parties
“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

 Michael S. Goldman

Michael S. Goldman

Managing Director

New York, United States
Oaklins TM Capital
 Steve  Hunter

Steve Hunter

Managing Director

Atlanta, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director

New York, United States
Oaklins TM Capital
 John  Dean

John Dean

Associate Director

Atlanta, United States
Oaklins TM Capital

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more